Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Additional Routes of Drug Administration01:18

Additional Routes of Drug Administration

Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Respiratory virus infections in decedents in a large, urban medical examiner's office.

Public health·2023
Same author

Behavioral and physiological responses to an inspired-air supplemental cooling system for dairy cows in free-stall housing.

Animal : an international journal of animal bioscience·2023
Same author

Truncation of <i>MAT1-2-7</i> Deregulates Developmental Pathways Associated with Sexual Reproduction in Huntiella omanensis.

Microbiology spectrum·2022
Same author

One key to fit all locks? Routine internal drainage to minimize seromas during thigh lift surgeries.

Annales de chirurgie plastique et esthetique·2022
Same author

Development of a novel stall design for dairy cattle: Part II. The effect of minimal stall partitioning on lying behavior, rumination, stall cleanliness, and preference.

Animal : an international journal of animal bioscience·2022
Same author

Development of a novel stall design for dairy cattle: Part I. The effect of an increased slope on lying behavior, rumination, cleanliness, and preference.

Animal : an international journal of animal bioscience·2022

関連する実験動画

Updated: Jul 14, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

フルチカゾンプロピオネートに対する異なる推進剤の間の肺の生物利用性の違い

A M Wilson, E J Sims, L C Orr

    Lancet (London, England)
    |October 26, 1999
    PubMed
    まとめ

    フルチカゾンプロピオネート吸入器の交換はリスクがある可能性があります. 最近のヒドロフッ素アルカン製剤は,古いヒドロフッ素炭化水素製剤よりも肺の生物利用性が低く,治療の有効性に影響を与える可能性があります.

    科学分野:

    • 薬理学 薬理学とは
    • 呼吸器医学とは
    • 薬物の配送システムです.

    背景:

    • フルチカゾンプロピオネートは,呼吸器疾患に対する広く使用されている吸入用コルチコステロイドです.
    • 以前の吸入器製剤では,クロロフルオロ炭素 (CFC) を推進剤として使用していました.
    • 現在の製剤は,環境規制のため,推進剤として主にヒドロフッ素アルカン (HFAs) を使用しています.

    研究 の 目的:

    • CFCおよびHFAベースの吸入器製剤の間のフルチカゾンプロピオネートの肺の生物利用性を比較する.
    • これらの異なる吸入器タイプを切り替えることで生じる臨床的影響を評価する.

    主な方法:

    • 肺の生物利用性は,腎上腺抑制を測定することによって間接的に評価され,これは,全身的に吸収されるフルチカゾンプロピオネートの既知の薬物動力学的効果である.
    • 患者や研究設計の詳細は概要に記載されていません.

    主要な成果:

    • 腎上腺抑制によって示される肺の生物利用性は,ヒドロフッ素アルカン (HFA) 推進剤の配方と比較して,クロロフッ素炭素 (CFC) 推進剤の配方では約2倍でした.
    • これは,HFA製剤で肺に到達する薬が著しく少ないことを示唆しています.

    結論:

    さらに関連する動画

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
    07:10

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

    Published on: May 20, 2019

    Intratracheal Administration of Dry Powder Formulation in Mice
    07:55

    Intratracheal Administration of Dry Powder Formulation in Mice

    Published on: July 25, 2020

    関連する実験動画

    Last Updated: Jul 14, 2026

    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
    07:28

    Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

    Published on: April 6, 2017

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
    07:10

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

    Published on: May 20, 2019

    Intratracheal Administration of Dry Powder Formulation in Mice
    07:55

    Intratracheal Administration of Dry Powder Formulation in Mice

    Published on: July 25, 2020

    • フルチカソンプロピオネート吸入器の製剤をマイクログラム相当で直接切り替えるのは,肺の生物利用性の有意な差異があるため,推奨されない場合があります.
    • 患者および医療従事者は,吸入器のタイプを変更する際の潜在的な治療等価性の問題を認識する必要があります.
    • CFCからHFA製剤に切り替えるときに適切な用量調整を確立するために,さらなる研究が必要になる可能性があります.